Tag: NASDAQ: ARAV

Business

Aravive Inc. (NASDAQ: ARAV) Drops After Releasing Preliminary Phase 1b of Phase 1b/2 AVB-500 Study In ccRCC Patients

Aravive Inc. (NASDAQ: ARAV) dropped 2.68% despite the company announcing positive initial results of the Phase 1b of the Phase 1b/2 trial in patients with clear cell renal cell carcinoma who received 15mg/kg of AVB-500 in combination with cabozantinib. Results from three study patients demonstrated that AVB-500 had favorable tolerability […]